Drugs / Dex2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01159288 | May 2010 → Dec 2015 | non-small cell lung carcinoma | Gustave Roussy, Cancer Campus, Grand Paris | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dex2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01159288 ↗ |
| Known as | Dex | “vaccinations with tumor antigen-loaded dendritic cell-derived exosomes (Dex)” NCT01159288 ↗ |
| Action | Activate | “Dex are able to activate the innate and adaptive immunity” NCT01159288 ↗ |
| Route | Other | “Intradermal injections of Dex once a week during 4 consecutive weeks.” NCT01159288 ↗ |